DEF: Senti Biosciences Sets Date for 2025 Annual Stockholders Meeting, Outlines Key Proposals

Senti Biosciences will hold its 2025 Annual Meeting of Stockholders virtually on June 25, 2025, to elect directors and ratify the appointment of KPMG LLP as its independent accounting firm.

Summary

• Senti Biosciences, Inc. will hold its 2025 Annual Meeting of Stockholders online on June 25, 2025, at 8:00 a.m. Pacific Time.
• Stockholders can attend and vote electronically at www.virtualshareholdermeeting.com/SNTI2025 using a 16-digit control number.
• The meeting's purposes include electing three Class III directors (Brenda Cooperstone, James (Jim) Collins, and Feng Hsiung) to serve until the 2028 annual meeting.
• Another key item is the ratification of KPMG LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2025.
• The Board of Directors has set April 28, 2025, as the record date for determining stockholders eligible to vote.
• The company is using the SEC's Notice and Access rule, providing proxy materials online and mailing a notice with instructions.
• Stockholders can request a free print version of the proxy materials.
• Votes can be cast via the Internet, QR code, telephone, or mail, with specific deadlines for each method.
• The Board of Directors recommends voting FOR the election of the director nominees and FOR the ratification of KPMG LLP's appointment.
• As of April 28, 2025, there were 26,072,527 shares of common stock outstanding, each entitled to one vote.
• The company's bylaws state that a majority of the voting power of outstanding shares constitutes a quorum.
• Stockholder proposals for the 2026 annual meeting must be received by December 31, 2025.
• The company's principal executive offices are located at 2 Corporate Drive, First Floor, South San Francisco, CA, 94080.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. It provides necessary information for shareholders to make informed decisions. The sentiment is slightly positive due to the routine nature of the proposals and the company's adherence to corporate governance best practices.

Positives

• The virtual format of the Annual Meeting is designed to enhance stockholder access, participation, and communication.
• Stockholders have the opportunity to submit questions during the Annual Meeting.
• The company is providing multiple methods for stockholders to vote, including online, by phone, and by mail.
• The Board of Directors is recommending well-qualified candidates for election as Class III directors.
• The Audit Committee has pre-approved all audit and non-audit services performed by KPMG LLP.

Future Outlook

The document outlines the proposals to be voted on at the upcoming annual meeting, including the election of directors and the ratification of the independent accounting firm, which will shape the company's governance and financial oversight for the coming year.

Management Comments

• Timothy Lu, M.D., Ph.D., Chief Executive Officer, encourages stockholders to vote either via the Internet or telephone.
• The Board of Directors believes that submitting the appointment of KPMG LLP to the stockholders for ratification is good corporate governance.

Industry Context

This proxy statement is a standard part of corporate governance, ensuring shareholders have the information needed to make informed decisions about the company's direction and oversight. The election of directors and ratification of auditors are routine but essential processes for publicly traded companies.

Comparison to Industry Standards

• The director compensation policy is designed to attract and retain qualified non-employee directors, providing compensation consistent with the company's objectives and aligning their interests with those of the stockholders.
• The company's approach to director independence aligns with Nasdaq listing standards, ensuring that independent directors can exercise independent judgment in carrying out their responsibilities.
• The company's compensation recovery policy is in accordance with the requirements of the SEC and Nasdaq listing rules, allowing the company to recover incentive-based compensation from executive officers in the event of a restatement of financial statements due to material noncompliance with financial reporting requirements.

Management Changes

Corporate Governance

Related Party Transactions

• Several related party transactions are disclosed, including the 2024 PIPE investment with participation from directors and significant stockholders.
• The company entered into a framework agreement with GeneFab, LLC, a company managed by Celadon Partners, LLC, which is affiliated with director Donald Tang.
• The company entered into a consulting agreement with Yvonne Li, former Interim Chief Financial Officer.

Stakeholder Impact

• Shareholders are directly impacted by the proposals being voted on, including the election of directors and the ratification of the independent accounting firm.
• Employees may be indirectly impacted by changes in corporate governance and executive compensation policies.
• The company's financial performance and strategic direction, as influenced by the Board of Directors, will ultimately impact all stakeholders.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals.
• The company will hold the Annual Meeting on June 25, 2025.
• The company will announce preliminary voting results at the Annual Meeting and file final results in a Form 8-K.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Senti Biosciences, Directors, KPMG, Stockholders, Voting, Corporate Governance, Financial Audit